Physician profile
Shalaine Brooke Corbilla
NPI 1134577216
$21,965.76
in general payments reported to CMS, 2019-2025
30 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.45 · 2022: $1,633 · 2023: $3,193 · 2024: $6,832 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,234 · Consulting Fee: $8,748 · Travel and Lodging: $2,076 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,233.88 |
| Consulting Fee | $8,748.00 |
| Travel and Lodging | $2,076.18 |
| Education | $251.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12,745.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,222.38 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,182.59 | 2022-2025 | Ofev, Stiolto Respimat, Jascayd |
| Glaxosmithkline, LLC. | $1,859.22 | 2022-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $399.88 | 2022-2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $398.45 | 2022-2024 | Wegovy, Saxenda |
| Insmed, INC. | $235.27 | 2024-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $233.23 | 2024-2025 | Winrevair |
| United Therapeutics Corporation | $212.47 | 2023-2024 | Tyvaso |
| Grifols USA, LLC | $212.29 | 2024-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $193.98 | 2023-2024 | |
| Amgen INC. | $169.69 | 2022-2025 | Evenity, Tezspire |
| Pulmonx Corporation | $136.21 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Abbvie INC. | $124.97 | 2023 | |
| Janssen Pharmaceuticals, INC | $120.08 | 2025 | Spravato |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $89.78 | 2022-2023 | |
| Antares Pharma, INC. | $87.81 | 2021-2022 | |
| Verona Pharma, INC. | $62.69 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $36.04 | 2025 | Dupixent |
| Millicent US INC | $33.32 | 2024 | Femring, Intrarosa |
| Harmony Biosciences LLC | $33.20 | 2024 | |
| Genentech USA, INC. | $27.74 | 2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $26.15 | 2025 | |
| Breas Medical, INC. | $21.78 | 2024 | Vivo 45 Ls |
| Pfizer INC. | $20.19 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.98 | 2022 | |
| Gilead Sciences, INC. | $17.38 | 2024 | Veklury |
| Endo Pharmaceuticals INC. | $16.53 | 2023 | Xiaflex |
| Therapeuticsmd, INC. | $13.43 | 2022 | |
| Avion Pharmaceuticals | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalaine Corbilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.